Objective. Type 2 deiodinase (Dio2) is an enzyme responsible for the conversion of T4 to T3. The Thr92Ala polymorphism has been shown related to an increased risk for developing type 2 diabetes mellitus (T2DM). The aim of this study is to assess the association between this polymorphism and glycemic control in T2DM patients as marked by the HbA1C levels. Design and Methods. The terms "rs225014," "thr92ala," "T92A," or "dio2 a/g" were used to search for eligible studies in the PubMed, Embase, and Cochrane databases and Google Scholar. A systematic review and meta-analysis of studies including both polymorphism testing and glycated hemoglobin (HbA1C) assays were performed. Results. Four studies were selected, totaling 2190 subjects. The pooled mean difference of the studies was 0.48% (95% CI, 0.18-0.77%), indicating that type 2 diabetics homozygous for the Dio2 Thr92Ala polymorphism had higher HbA1C levels. Conclusions. Homozygosity for the Dio2 Thr92Ala polymorphism is associated with higher HbA1C levels in T2DM patients. To confirm this conclusion, more studies of larger populations are needed.
Introduction
Type 2 deiodinase (Dio2) is localized on the long arm of the 14th human chromosome in 14q24.3. It is an intracellular enzyme which catalyzes the conversion of thyroxine (T4) to its active form triiodothyronine (T3) [1] . Therefore, Dio2 is a very important regulator for tissue specific metabolic activity.
A single nucleotide polymorphism in the Dio2 gene (A/G) results in a threonine change to alanine (Thr92Ala) at codon 92 [2] . The Dio2 Thr92Ala polymorphism has been reported to be associated with many disorders, such as osteoarthritis [3, 4] , hypertension [5] , Graves' disease [6] , Kashin-Beck disease [7] , bipolar disorder [8] , depression [9] , and cognitive impairment [10, 11] . In addition, many studies have shown that the Thr92Ala polymorphism is related to type 2 diabetes mellitus (T2DM), insulin resistance, and body mass index (BMI) [2, [12] [13] [14] [15] [16] [17] [18] . However, the relationship between the Thr92Ala polymorphism and glycemic control in T2DM patients is unclear. The aim of this meta-analysis is to determine whether the Dio2 Thr92Ala polymorphism is associated with glycemic control in T2DM patients as marked by the HbA1C level.
Design and Methods

Search Strategy.
A literature search was conducted by two investigators (Xiaowen Zhang and Jie Sun) in February 2016, using the PubMed, Embase, and Cochrane databases and Google Scholar. The terms Thr92Ala, T92A, rs225014, and Dio2 a/g were used. Reference lists in the articles and recent reviews were also searched.
Inclusion Criteria.
Studies were selected for metaanalysis if they met the following criteria: (1) being observational studies related to Dio2 polymorphism and (2) including T2DM patients along with their respective glycated hemoglobin (HbA1C) levels. 
Quality Assessment. Two investigators (Yaqiu Jiang and
Wenqing Han) assessed the quality of the selected studies using the Newcastle-Ottawa Scales (NOS) [19] . Information regarding selection, comparability, and exposure was evaluated for each study. Only the studies with more than 5 stars based on the NOS scale were included in this meta-analysis. 
Results
Ninety-five studies were initially retrieved from the databases and Google Scholar. Seventy-three articles were excluded after reading the titles and abstracts as they were not related to T2DM. A full-text review of the remaining 22 articles was conducted and 4 articles were identified as eligible ( Figure 1 ). Table 1 summarized the characteristics of the selected articles.
When analyzed in a recessive inheritance model, the meta-analysis of 4 studies including data on the association between Thr92Ala polymorphism and HbA1C levels showed that the mean difference (MD) was 0.48% (95% CI, 0.18∼ 0.77%) (Figure 2 ), indicating that the HbA1C levels in T2DM patients with Dio2 Thr92Ala homozygosity are 0.48% higher than the non-Ala T2DM patients. Both the statistical test ( = 0.10) and 2 statistic ( 2 = 52%) showed moderate heterogeneity; therefore, a random effects model was used. Sensitivity analyses by sequential omission of each study resulted in similar results, with calculated MDs of 0.44% (95% CI, 0.11∼0.76%), 0.60% (95% CI, 0.30∼0.89%), 0.33 (95% CI, 0.09∼0.57%), and 0.55% (95% CI, 0.07∼1.02%), respectively.
When analyzed in a dominant inheritance model, one study was excluded because Thr/Thr and Ala/Thr genotypes were grouped and compared with Ala/Ala genotype [14] . The meta-analysis of the remaining 3 studies showed that the mean difference (MD) was 0.05% (95% CI, −0.16∼0.26%) (Figure 3 ), indicating that HbA1C levels of T2DM patients with Dio2 Thr92Ala allele were not higher. Both the statistical test ( = 0.69) and 2 statistic ( 2 = 0%) showed no heterogeneity; therefore, a fixed effects model was used.
Articles identified through database search (n = 95)
Articles excluded after reading title and abstract (n = 73)
Articles selected for more detailed evaluation (n = 22)
Reasons for exclusion: 7 excluded because they were reviews and not original studies; 5 excluded because HbA1C assays were not done; 3 excluded because the patients did not have T2DM; 2 excluded because the data were not extractable; 1 repeated study.
Full-text articles excluded (n = 18)
Studies included in meta-analysis (n = 4) Sensitivity analyses by sequential omission of each study resulted in similar results, with calculated MDs of 0.06% (95% CI, −0.16∼0.29%), −0.01% (95% CI, −0.26∼0.24%), and 0.13% (95% CI, −0.20∼0.45%), respectively. In order to uncover the source of heterogeneity, subgroup analysis was performed (Figure 4 ). Dhanunjaya's study is different from the other 3 studies because the BMI is smaller and racial population is Indian. We found that this study was the main source of heterogeneity.
Discussion
The results of the previous studies regarding the association between the Dio2 Thr92Ala polymorphism and glycemic control in T2DM patients have been contradictory [2, 14, 20, 21] . This current meta-analysis found that people who are homozygous for Thr92Ala had 4.8% higher HbA1C levels, suggesting that Thr92Ala homozygosity is associated with worse glycemic control in T2DM patients. To our knowledge, this is the first meta-analysis to investigate the effect of Dio2 Thr92Ala polymorphism on HbA1C levels in T2DM patients.
Some studies assumed that it is a recessive inheritance model because of "Thr/Thr and Thr/Ala genotypes showing similarities in biochemical characteristics" [14, 20] . However, we believe that further studies are still needed and analyses performed in dominant inheritance model are necessary. There are no significant differences in Ala/Ala + Ala/Thr versus Thr/Thr when it was analyzed in a dominant inheritance model.
Among the four included studies, three were conducted in Brazil, thus related to Brazilian population [2, 14, 21] , and one was done in India [20] . In the Brazilian population, the Ala allele frequency is about 0.4; however, in the Indian population, the frequency of this allele is 0.6, which is Test for overall effect: Z = 3.14 (P = 0.002) Test for subgroup differences: 2 = 3.58, df = 1 (P = 0.06); I 2 = 72.0% [22] . The Dio2 Thr92A and peroxisome proliferator-activated receptor-gamma2 (PPAR 2) Pro2Ala polymorphisms interact in the modulation of systolic and diastolic blood pressure and metabolic syndrome [23] . Furthermore, a combination of this polymorphism and Journal of Diabetes Research 5 3-adrenergic receptor Trp63Arg results in an increased BMI, indicating a synergistic effect of these two polymorphisms [13] .
Some studies have shown that the Thr92Ala polymorphism is related to type 2 diabetes mellitus (T2DM), insulin resistance. However, the Framingham Heart Study showed that there is no association of Thr92Ala polymorphism with T2DM or hypertension risks [17, 24] . Though Dio2 velocity was decreased in the thyroid and skeletal muscle in individuals homozygous for the Ala allele [2] , the Thr to Ala substitution at codon 92 is not near the enzyme's active site [25] . Moreover, the Thr92Ala mutation does not affect Dio2 activity in vitro, indicating that Thr92Ala may be a marker, rather than a functional polymorphism of the decreased enzyme velocity.
The limitations of this meta-analysis are as follows: (1) T2DM is a heterogeneous disease [26] , and thus the contribution of a single gene may be restricted; (2) the size of subjects involved in this meta-analysis was relatively small; (3) only Brazilian and Indian population were included and these findings may not be applied to other racial groups. More studies on this topic are needed since genetic association studies should include larger populations in order to ensure accurate conclusions.
Conclusion
In conclusion, homozygosity for the Dio2 Thr92Ala polymorphism might be associated with worse glycemic control in type 2 diabetics as marked by the HbA1C levels. Further epidemiological studies of larger populations from different geographic regions are needed.
